Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-20
2009-08-18
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S323000, C514S406000, C514S418000, C544S144000, C546S201000, C546S256000, C548S364700, C548S466000, C548S469000, C548S492000
Reexamination Certificate
active
07576082
ABSTRACT:
The invention describes compounds of the general formula Ior the pharmaceutically acceptable salts thereof,wherein R1, R2, R3and X are herein described,a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show activity as antiproliferative agents and may be especially useful for the treatment of cancer.
REFERENCES:
patent: 2759935 (1956-08-01), Speeter et al.
patent: 3441570 (1969-04-01), Meyer
patent: 3686210 (1972-08-01), Bell et al.
patent: 4020179 (1977-04-01), Irvine
patent: 6511974 (2003-01-01), Dusza et al.
patent: 55 129284 (1980-06-01), None
patent: 2000 191661 (2000-07-01), None
patent: WO 98/02432 (1998-01-01), None
patent: WO 98/54167 (1998-12-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 03/008407 (2003-01-01), None
patent: WO 03/078394 (2003-09-01), None
patent: WO 2006/080574 (2006-08-01), None
Christopher Hulme, et al., Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 175-178 (1998), XP002405133.
F.D. Dopp, et al., J. Heterocyclic Chem., vol. 17, No. 9, pp. 1329-1330 (1980), XP002405134.
Gordon N. Walker, et al., J. Med. Chem., vol. 8, pp. 626-637 (1965), XP002405135.
Stanislav Kafka, et al., J. Org. Chem., vol. 66, pp. 6394-6399 (2001), XP002405136.
Amarnath Natarajan, et al., J. Med. Chem., vol. 47, pp. 1882-1885 (2004), XP002405137.
James C. Powers, J. Org. Chem., vol. 30, pp. 2534-2540 (1965), XP002405138.
Sengodagounder Muthusamy, et al., Synlett, vol. 2002, No. 11, pp. 1783-1786 (2002), XP002405139.
Ward C. Sumpter, J. Am. Chem Soc., vol. 54, pp. 2917-2918 (1932), XP002405141.
H.E. Zaugg, et al., J. Am. Chem. Soc., vol. 84, pp. 4574-4578 (1962), XP002418406.
Steven P. Govek, et al., J. Am. Chem. Soc., vol. 123, pp. 9468-9469 (2001), XP002418407.
Rita Kapiller-Dezofi, et al., New J. Chem., vol. 28, pp. 1214-1220 (2004), XP002418408.
David W. Robertson, et al., J. Med. Chem., vol. 29, pp. 1832-1840 (1986), XP002418409.
Kazuo Takayama, et al., Tetrahedron Letters, vol. 5, pp. 365-368 (1973), XP002418410.
Audris Huang, et al., J. Am. Chem. Soc., vol. 126, pp. 14043-14053 (2004), XP002418411.
Masaru Ogata, et al., Eur. J. Med. Chem.—Chimica Therapeutica, vol. 16, No. 4, pp. 373-379 (1981), XP00907847.
Istvan Moldvai, et al., Arch. Pharm. Pharm. Med. Chem., vol. 329, pp. 541-549 (1996), XP009078456.
Hossein Pajouheish, et al., J. Pharm. Sci., vol. 72, No. 3, pp. 318-321 (1983), XP009078411.
Krishna C. Joshi, et al., Journal of Fluorine Chemistry, vol. 44, pp. 59-72 (1989), XP002418412.
Piyasena Hewawasam, et al., Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 1023-1026 (2002), XP002418413.
Santiago Barroso, et al., J. Org., Chem., vol. 69, pp. 6821-6829 (2004), XP002418416.
Paul Aeberli, et al., J. Org. Chem., vol. 33, No. 4 pp. 1640-1643 (1968), XP002418417.
A. Walser, et al., J. Org. Chem., vol. 38, No. 3, pp. 449-456 (1973), XP002418418.
Javad Azizian, et al., Synthesis, vol. 2005, No. 7, pp. 1095-1098 (2005), XP 002418427.
Andrew Fensome, et al., Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 3487-3490 (2002), XP002418428.
T.V. Rajanbabu, et al., J. Org. Chem., vol. 51, pp. 1704-1712 (1986), XP002418429.
Karnail S. Atwal, et al., J. Med. Chem., vol. 39, pp. 304-313 (1996), XP002418430.
Balazs Volk, et al., Eur. J. Org. Chem., pp. 3991-3996 (2003), XP002418431.
Keith Smith, et al., J. Chem. Soc. Perkin Trans. 1, vol. 1999, pp. 2299-2303 (1999), XP002418432.
R.L. Hinman, et al., J. Org. Chem., vol. 29, pp. 2431-2437 (1964), XP002418433.
Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196.
Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at p. 1456-1457.
Kraynack, E. A.; Dalgard, J. E.; Gaeta, F. C. A.Tetrahedron Letters, 1998, 39, 7679-7682.
P.; Erway, et al.,J. Med. Chem. 2002, 45, 1487-1499.
Elliott, I. W.; Rivers, P.J. Org. Chem. 1964, 29, 2438-2440.
Andreani, A.; et al.,Eur. J. Med. Chem. 1990, 25, 187-190.
Luk Kin-Chun
So Sung-Sau
Zhang Jing
Zhang Zhuming
Hoffman-La Roche Inc.
Johnston George W.
Rocha-Tramaloni Patricia S.
Saeed Kamal A
Shterengarts Samantha L
LandOfFree
Oxindole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxindole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxindole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4085679